Noh SH, Park SR, Yang HK et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (Classic): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15:1389–1396. https://doi.org/10.1016/S1470-2045(14)70473-5

Article  CAS  PubMed  Google Scholar 

Wang XB, Yang LT, Zhang ZW et al (2008) Pancreaticoduodenectomy for advanced gastric cancer with pancreaticoduodenal region involvement. World J Gastroenterol 14:3425–3429. https://doi.org/10.3748/wjg.14.3425

Article  PubMed  PubMed Central  Google Scholar 

Chan WH, Cheow PC, Chung AY et al (2008) Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results. ANZ J Surg 78:767–770. https://doi.org/10.1111/j.1445-2197.2008.04646.x

Article  PubMed  Google Scholar 

Nunobe S, Hiki N, Ohyama S et al (2008) Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph-node metastases. Langenbecks Arch Surg 393:157–162. https://doi.org/10.1007/s00423-007-0248-4

Article  PubMed  Google Scholar 

Pflüger MJ, Felsenstein M, Schmocker R et al (2020) Gastric cancer following pancreaticoduodenectomy: experience from a high-volume center and review of existing literature. Surg Open Sci 2:32–40. https://doi.org/10.1016/j.sopen.2020.06.003

Article  PubMed  PubMed Central  Google Scholar 

Shchepotin IB, Chorny VA, Nauta RJ et al (1998) Extended surgical resection in T4 gastric cancer. Am J Surg 175:123–126. https://doi.org/10.1016/S0002-9610(97)00268-7

Article  CAS  PubMed  Google Scholar 

Terashima M, Yoshikawa T, Boku N et al (2020) Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Jpn J Clin Oncol 50:528–534. https://doi.org/10.1093/jjco/hyaa005

Article  PubMed  Google Scholar 

Yura M, Takano K, Adachi K et al (2021) Pancreaticoduodenectomy after neoadjuvant chemotherapy for gastric cancer invading the pancreatic head: a case report. World J Gastroenterol 27:534–544. https://doi.org/10.3748/wjg.v27.i6.534

Article  PubMed  PubMed Central  Google Scholar 

Kondo M, Nishino S, Yamashita D et al (2020) Complete response of locally advanced gastric cancer with pancreatic invasion and gastric outlet obstruction after neoadjuvant chemotherapy with S-1 and oxaliplatin. Case Rep Oncol 13:716–720. https://doi.org/10.1159/000507983

Article  PubMed  PubMed Central  Google Scholar 

Suzuki S, Takahashi A, Ishikawa T et al (2021) Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry. Gastric Cancer 24:545–566. https://doi.org/10.1007/s10120-021-01178-5

Article  PubMed  Google Scholar 

Saka M, Mudan SS, Katai H et al (2005) Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer 8:1–5. https://doi.org/10.1007/s10120-004-0298-z

Article  PubMed  Google Scholar 

Li DB, You J, Wang SJ et al (2019) Pancreaticoduodenectomy for locally advanced gastric cancer: results from a pooled analysis. Asian J Surg 42:477–481. https://doi.org/10.1016/j.asjsur.2018.09.005

Article  PubMed  Google Scholar 

Kubota T, Hiki N, Sano T et al (2014) Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol 21:891–898. https://doi.org/10.1245/s10434-013-3384-9

Article  PubMed  Google Scholar 

Russell TB, Labib PL, Bowles M et al (2023) Serious complications of pancreatoduodenectomy correlate with lower rates of adjuvant chemotherapy: would high-risk patients benefit from neoadjuvant therapy? Eur J Surg Oncol 49:142–149. https://doi.org/10.1016/j.ejso.2022.08.032

Article  PubMed  Google Scholar 

Fukagawa T, Katai H, Mizusawa J et al (2018) A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer 21:68–73. https://doi.org/10.1007/s10120-017-0701-1

Article  PubMed  Google Scholar 

Becker K, Langer R, Reim D et al (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253:934–939. https://doi.org/10.1097/SLA.0b013e318216f449

Article  PubMed  Google Scholar 

Zhang X, Liang H, Li Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22:1081–1092. https://doi.org/10.1016/S1470-2045(21)00297-7

Article  CAS  PubMed  Google Scholar 

Wang XZ, Zeng ZY, Ye X et al (2020) Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 12:37–53. https://doi.org/10.4251/wjgo.v12.i1.37

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin P, Liu H, Ma FH et al (2021) Retrospective analysis of surgically treated pT4b gastric cancer with pancreatic head invasion. World J Clin Cases 9:8718–8728. https://doi.org/10.12998/wjcc.v9.i29.8718

Article  PubMed  PubMed Central  Google Scholar 

Tokunaga M, Sato Y, Nakagawa M et al (2020) Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today 50:30–37. https://doi.org/10.1007/s00595-019-01896-5

Article  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2

Article  CAS  PubMed  PubMed Central  Google Scholar